|
Objective To investigate the S100A9 in normal ovarian tissue , benign ovarian tumors and primary epithelial ovarian carcinoma with epithelial ovarian cancer biological behavior . Methods using tissue microarray and immunohistochemical methods in 63 patients with primary epithelial ovarian cancer , 20 cases of benign ovarian tumors and 22 cases of normal ovarian tissue S100A9 protein expression , simultaneous analysis of S100A9 in primary epithelial ovarian carcinoma and clinical surgery - pathological stage (FIGO, 2000), degree of differentiation , histological type , lymph nodes, omentum metastasis , ascites , location ( unilateral or bilateral ) and the onset of age. Application SPSS11.5 statistical analysis , semi-quantitative data using t test , P <0.05 for the difference was statistically significant . The results of primary epithelial ovarian carcinoma S100A9 was significantly higher than in normal ovarian tissues and benign ovarian tumors , the difference was significant (P <0.05); S100A9 in primary epithelial ovarian cancer in stage Ⅲ ~ Ⅳ group , poorly differentiated group and omental metastases showed high expression were compared with the control group , the difference was significant (P <0.05); while S100A9 expression and histological type, ascites and lymph node metastasis (P > .05 ) . 20 cases of carcinoma nuclei expression , the rest of cytoplasm . Conclusion S100A9 may be involved in epithelial ovarian cancer occurrence, development and metastasis , the Joint Monitoring S100A9 and other tumor markers in clinical practice is expected to improve early diagnosis of ovarian cancer , disease monitoring and prognosis .
|